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The transport of L-leucine by two human breast cancer cell lines has been examined. L-Leucine uptake by MDA-MB-231 and MCF-7
cells was via a BCH-sensitive, Na+-independent pathway. L-Leucine uptake by both cell lines was inhibited by L-alanine, D-leucine and to
a lesser extent by L-lysine but not by L-proline. Estrogen (17h-estradiol) stimulated L-leucine uptake by MCF-7 but not by MDA-MB-231
cells. L-Leucine efflux from MDA-MB-231 and MCF-7 cells was trans-stimulated by BCH in a dose-dependent fashion. The effect of
external BCH on L-leucine efflux from both cell types was almost abolished by reducing the temperature from 37 to 4 jC. There was,
however, a significant efflux of L-leucine under zero-trans conditions which was also temperature-sensitive. L-Glutamine, L-leucine, D-
leucine, L-alanine, AIB and L-lysine all trans-stimulated L-leucine release from MDA-MB-231 and MCF-7 cells. In contrast, D-alanine and
L-proline had little or no effect. The anti-cancer agent melphalan inhibited L-leucine uptake by MDA-MB-231 cells but had no effect on L-
leucine efflux. Quantitative real-time PCR revealed that LAT1 mRNA was approximately 200 times more abundant than LAT2 mRNA in
MCF-7 cells and confirmed that MDA-MB-231 cells express LAT1 but not LAT2 mRNA. LAT1 mRNA levels were higher in MCF-7
cells than in MDA-MB-231 cells. Furthermore, LAT1 mRNA was more abundant than CD98hc mRNA in both MDA-MB-231 and MCF-
7 cells. The results suggest that system L is the major transporter for L-leucine in both MDA-MB-231 and MCF-7 cells. It is possible that
LAT1 may be the major molecular correlate of system L in both cell types. However, not all of the properties of system L reflected those
of LAT1/LAT2/CD98hc.
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1. Introduction identified. Two of them are heterodimers which consist ofSystem L is a mechanism which transports neutral amino
acids across the plasma membrane. It operates in a manner
which does not require Na+ and is inhibited by BCH (2-
amino-2-norbornane carboxylic acid) (e.g. see Refs. [1,2]).
As well as being involved in amino acid transport, it is
becoming apparent that system L mediates the transport of
the thyroid hormone T3 and could also be involved in drug
and trace element metabolism [3–8]. Recent molecular
studies have borne out earlier predictions, based on kinetic
analysis, that system L is not a single transporter [9–15]. To
date, three molecular correlates of system L have been0005-2736/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
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E-mail address: shennand@hri.sari.ac.uk (D.B. Shennan).a light chain (LAT1 or LAT2) joined to a heavy chain
(CD98hc) by a disulfide bond. LAT1 and LAT2 are pre-
dicted to have 12 transmembrane spanning domains where-
as CD98 hc, a highly glycosylated protein, is believed to
have one transmembrane helix. It is accepted that the light
chains act as the catalytic subunit. LAT2 is generally
believed to transport a wider range of neutral amino acids
than LAT1 [2]. The third molecular correlate of system L
(LAT3) is structurally distinct from LAT1 and LAT2, does
not require CD98hc for its functional expression and
appears to have a narrow substrate specificity [16].
It is apparent that system L expression may be related to
tumour growth [17–19]. For example, LAT1(TA1/E16) is
expressed in colorectal cancer but not in the normal colon
[17]. In addition, LAT1, in cooperation with CD98hc,
appears to promote the growth of rat liver tumour lesions
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expressed in a variety of human tumour cell lines [20]. In
this connection, we have recently shown that two human
breast cancer cell lines, namely MDA-MB-231 and MCF-7,
respectively estrogen receptor-negative and-positive cells,
express system L at the functional and molecular level [21].
MDA-MB-231 and MCF-7 cells exhibited Na+-indepen-
dent, BCH-sensitive a-aminoisobutyric acid transport. Fur-
thermore, MCF-7 cells expressed LAT1, LAT2 and CD98hc
mRNA whereas MDA-MB-231 cells expressed only LAT1
and CD98hc mRNA. An unusual finding was that L-lysine,
generally regarded not to be a substrate, interacted with
system L in both cell lines, albeit with low affinity.
System L in human breast cancer cells could be an
important diagnostic tool and/or therapuetic target. For
example, LAT1 (E16) is expressed in primary breast cancer
tissue [17] and thus could play an important role in tumour
cell proliferation by providing certain essential neutral
amino acids. There is also good evidence that melphalan,
an alkylating agent used in the treatment of breast cancer,
gains access to MCF-7 cells via system L [22]. The present
study was undertaken to confirm and extend our recent
findings relating to the expression and activity of system L
in cultured human breast cancer cells. In this paper we have
examined the kinetics, regulation and substrate specificity of
L-leucine transport by MDA-MB-231 and MCF-7 cells to
see if the properties of system L correlate with those of
LAT1/LAT2/CD98hc. In this connection, we have examined
the relative expression of LAT1, LAT2 and CD98hc in the
two cell lines using real-time quantitative PCR. In addition,
we have attempted to establish if system L in human breast
cancer cells can function as a uniporter as well as an
exchange mechanism as the mode of operation is important
regarding the relationship between system L and other
amino acid transporters [23].2. Methods
2.1. Cell culture
MCF-7 and MDA-MB-231 cells were cultured in Dul-
becco’s Modified Eagle Medium (DMEM) supplemented
with L-glutamine (2 mM), heat-inactivated fetal bovine
serum (10%), penicillin (50 IU/ml) and streptomycin (50
Ag/ml). Cells were seeded in 35-mm culture wells contain-
ing 2 ml of culture DMEM medium (with supplements) at a
density of 0.3–1.0 106 cells per well. The cells were
cultured for 1–3 days at 37 jC in a gas phase of air with
5% CO2 and were used at 60–90% confluency.
2.2. Culture of MCF-7 and MDA-MB-231 cells in the
presence of 17b-estradiol
MCF-7 and MDA-MB-231 cells were cultured in phenol
red-free DMEM supplemented with L-glutamine (2 mM),charcoal-stripped fetal bovine serum (10%), penicillin (50
IU/ml) and streptomycin (50 Ag/ml). Cells were initially
cultured in 75-cm2 flasks containing 12 ml of culture
medium for 3 days. Following this the cells were harvested
using trypsin and seeded in 35-mm culture wells at a density
of 5 105 cells per well and cultured for a further 48 h in
phenol red-free DMEM containing the supplements de-
scribed above. The culture medium was supplemented with
17h-estradiol (prepared in ethanol) to give a final concen-
tration of 10 nM. Control culture wells were supplemented
with ethanol alone (1Al/ml).
2.3. Measurement of L-leucine and L-alanine uptake
The uptake of L-leucine and L-alanine by MDA-MBA-
231 and MCF-7 cells was assayed respectively using
[3H]leucine and [3H]alanine as tracer. The culture medium
was removed and the cells were washed three times with 3
ml of a buffer containing (mM) 0.01 L-leucine or L-alanine,
135 NaCl or choline-Cl, 5 KCl, 2 CaCl2, 1 MgSO4, 10
glucose and 10 Tris–MOPS, pH 7.4 and were preincubated
for 5 min at 37 jC in 2 ml of an appropriate buffer (see
figure legends for precise details). L-Leucine and L-alanine
uptake experiments were started by adding 1 ml of a buffer
similar in composition to that just described except that it
also contained 0.4 ACi [14C]sucrose together with either 1.0
ACi [3H]leucine or 1.0ACi [3H]alanine. At a pre-determined
time, the incubation buffer containing the radioisotopes was
removed and the cells were washed four times with 3 ml of
an ice-cold buffer containing (mM) 135 choline-Cl, 5 KCl, 2
CaCl2, 1 MgSO4, 10 glucose and 10 Tris–MOPS, pH 7.4.
Following the washing procedure, the cells were lysed by
incubating in 1 ml of distilled water for at least 3 h, during
which time the lysate was frequently agitated. A portion of
the lysate (0.5 ml) was mixed with 0.5 ml of 10% trichloro-
acetic acid (TCA) and left to stand for at least 15 min. The
mixture was centrifuged for 3 min at 12,000 g and 0.5 ml
of the supernatant was prepared for counting by adding 10
ml of UltimaGold liquid scintillation fluid. Samples of each
lysate (0.1 ml) were taken to determine the protein content
using the Lowry method. The specific activity of the
isotopes in the incubation medium was determined by
counting the amount of radioactivity associated with 10
Al of buffer. L-Leucine and L-alanine uptake by MCF-7 and
MDA-MB-231 cells was calculated according to Eq. (1):
½amino acidc ¼ ð½amino acidt  ðF½amino acidmÞÞ=P
ð1Þ
where [amino acid]c is the amount of L-leucine or L-alanine
in the cells (pmol/mg protein), [amino acid]t is the total
amount of L-leucine or L-alanine in the lysate (pmol),
[amino acid]m is the amount of L-leucine or L-alanine in
the incubation medium (pmol), F is the ratio of radiolabelled
sucrose in the lysate to that in the incubation medium and P
is the amount of protein in the lysate (mg).
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The efflux of L-leucine from MCF-7 and MD-MB-231
cells was measured using [3H] leucine or [14C] leucine as
tracer. The culture medium was removed and the cells were
washed three times with 2 ml of a buffer containing (mM)
135 choline-Cl, 5 KCl, 2 CaCl2, 1 MgSO4, 10 glucose and
10 Tris–MOPS, pH 7.4. The cells were loaded with radio-
labelled L-leucine over a period of 10 min by incubating in 2
ml of a buffer similar in composition to that just described
except that it also contained 1.0 ACi/ml [3H] leucine or 0.25
ACi/ml [14C] leucine. After loading, the cells were washed
four times in rapid succession with a radioactive-free buffer
similar in composition to that described above. The unidi-
rectional efflux of radiolabelled leucine from the cultured
cells was measured by the sequential addition and removal
of 2 ml of buffer (see figure legends for precise details of
composition) at 1-min intervals. At the end of the efflux
wash-out period, the cells were incubated in 2 ml of 10%
TCA for at least 3 h. Following this incubation, the samples
were centrifuged at 12,000 g for 5 min. The resultant
supernatant (1 ml) was prepared for counting by adding 10
ml of UltimaGold liquid scintillation fluid. The fractional
release was calculated for each 1-min collection period. This
was taken as the ratio of the amount of radioactivity lost
from the cells per minute to the amount of radioactivity in
the cells at the start of the collection period. The radioac-
tivity associated with the cells at a given time was deter-
mined by adding the radioactivity left in the cells at the end
of the incubation to the radioactivity lost by the cells in each
of the collection periods in reverse order. Efflux time
courses were also analysed by plotting ln (Nt/N0) as a
function of time where Nt represents the amount of radio-
activity remaining in the cells at time t and N0 is the amount
of radioactivity associated with the cells at the start of the
experiment. The negative slopes of the graphs provided a
measure of the unidirectional efflux rate constants.
2.5. RNA isolation and quantitative RT-PCR
Total cellular RNA was isolated from the breast cancer
cells using Triazol reagent (InVitrogen). RNA was sus-
pended in water and the concentration determined by the
A260, where one unit of absorbance measured at 260 nm
corresponded to 40 Ag of RNA. The integrity of the RNA
was checked by electrophoresis in a 1.2% agarose gel
containing 2.2 M formaldehyde and 0.5 Ag/ml of ethidium
bromide [24].
PCR primers for LAT1, LAT2 and CD98hc were
designed from the sequences available in GenBank (ac-
cession numbers: LAT1,AF104032; LAT2,AF171669;
CD98(4F2hc),AH001404). Primer pairs were designed to
different exons to prevent the amplification of any con-
taminating DNA. The primer pairs used in the PCRs
were as follows: LAT1, forward 5V GAGGCCG-
TGGCCGTGGACTTCGGGAACTAT 3V and reverse
D.B. Shennan et al. / Biochimica e2085VGGCGATCAGGAAGAGGCAGGCCAGGATGAA 3V;
LAT2, forward 5VAGCCTGATATCCCCGCCCCATCAA-
GATCA 3V and reverse 5V TTGGCGGGACCAAGG-
CAGGGAGGTAGGATA 3V; CD98hc, forward 5V
CTGGCGGGTCTGAAGGGGCGTCTCGATTAC 3V and
reverse 5V TCACCCCCGTAGTTGGGAGTAAGGTC-
CAGA 3V. The expected sizes of the PCR products were
420 bp for LAT1, 422 bp for LAT2 and 224 bp for
CD98hc. Confirmation that the RT-PCR products were
those expected was done by sequencing or digestion with
specific restriction endonucleases [21].
cDNAs were prepared from three individual preparations
of MCF-7 and MDA-MB-231 cells. Aliquots (1 Ag) of total
RNA were reverse transcribed using MMLV reverse tran-
scriptase (Promega) and random hexamers (Pharmacia).
Quantitative real-time PCR was performed using Light-
cycler SYBR-green technology (Roche) using cDNA equiv-
alent to 40 ng of total RNA. The data were collected at a
temperature just below the start of the melting curve. The
amount of specific sequence in the input DNA was then
determined by reference to a dilution series of a plasmid
pCD98L1L2 (pBluescriptII SK+ into which the PCR prod-
ucts of CD98, LAT1, and LAT2 were cloned) performed at
the same time in duplicate.3. Materials
L-[4,5-3H]Leucine (157 Ci/mmol), L-[U-14C]leucine (306
mCi/mmol), L-[2,3]alanine (52 Ci/mmol) and [U-14C]su-
crose (643 mCi/mmol) were purchased from Amersham
plc, Bucks, UK. All other chemicals, unless otherwise
indicated, were obtained from Sigma, Poole, Dorset, UK.4. Statistics
Differences were assessed using Student’s paired or
unpaired t-test as appropriate and were considered signifi-
cant when P < 0.05.5. Results
5.1. L-Leucine uptake by MDA-MB-231 and MCF-7 cells
Preliminary experiments revealed that the time course of
L-leucine uptake, measured under sodium-free conditions,
by MDA-MB-231 and MCF-7 cells was linear up to 1 min
(results not shown). Therefore, in subsequent experiments,
L-leucine uptake was assayed after 30 s of incubation. We
examined the effect of BCH on L-leucine uptake in the
absence and presence of extracellular Na+. Fig. 1 shows that
L-leucine influx into MDA-MB-231 and MCF-7 cells was
not affected by replacing extracellular sodium with choline.
Fig. 1 also shows that L-leucine uptake into both cell types
Fig. 2. The kinetics of L-leucine and L-alanine uptake by MCF-7 and MDA-
MB-231 cells. The points denoted (.) and (o) respectively represent L-
leucine and L-alanine uptake by MCF-7 cells and the points denoted (n)
represent L-leucine uptake by MDA-MB-231 cells. The incubation medium
contained (mM) 0.01–2 L-leucine or L-alanine, 135 choline-Cl, 5 KCl, 2
CaCl2, 1 MgSO4, 10 glucose and 10 Tris–MOPS, pH 7.4. Uptake was
assayed at 37 jC after 30 s of incubation. Each point is the meanF S.E. of
four experiments for L-leucine uptake and three experiments for L-alanine
uptake.
Fig. 1. The effect of BCH in the presence and absence of extracellular Na+ on L-leucine uptake by MDA-MB-231 and MCF-7 cells. The incubation medium
contained (mM) 0.01 L-leucine, 135 choline-Cl or NaCl, 5 KCl, 2 CaCl2, 1 MgSO4, 10 glucose and 10 Tris–MOPS, pH 7.4. BCH, when required, was used at
a concentration of 10 mM. Uptake was assayed at 37 jC after 30 s of incubation. The results shown are the meansF S.E. of four to five experiments,
respectively, when MDA-MB-231 and MCF-7 cells were used.
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of 10 mM. It is evident that the effect of BCH on L-leucine
uptake was not affected by replacing extracellular Na+ with
choline. It appears, therefore, that the vast majority of L-
leucine uptake into the two human breast cancer cell lines is
via system L. In contrast, L-alanine uptake by both cell lines
was significantly reduced by substituting extracellular Na+
with choline. L-Alanine (10 AM) uptake by MDA-MB-231
cells in the presence and absence of extracellular Na+
(choline replacement) was, respectively, 545.8F 84.4 and
36.2F 15.0 pmol/mg protein/30 s (F S.E.; n = 3). L-Alanine
uptake by MCF-7 cells in the presence and absence of
extracellular Na+ was, respectively, 476.2F 88.6 and
23.6F 8.7 pmol/mg protein/30 s (F S.E.; n = 3).
We tested the effect of a variety of external amino acids
on L-leucine influx into MDA-MB-231 and MCF-7 cells.
The amino acids we examined were L-proline, L-alanine, L-
lysine, D-leucine and unlabelled L-leucine. Each amino acid
was added to the incubation medium to give a final
concentration of 10 mM. L-Leucine uptake (10 AM) was
measured under Na+-free conditions. L-Leucine uptake into
MDA-MB-231 cells was inhibited by unlabelled L-leucine
(96.3 F 0.6%; P < 0.001), D-leucine (96.8 F 0.5%;
P < 0.01), L-alanine (91.7F 1.7%; P < 0.001) and L-lysine
(65.7F 6.9%; P < 0.01). On the other hand, L-proline was
without effect. Similarly, L-leucine uptake by MCF-7 cells
was inhibited by unlabelled L-leucine (96.8F 0.5%; P <
0.01), D-leucine (92.7F 2.3%; P < 0.05), L-alanine (76.4F
3.0%; P < 0.002) and L-lysine (34.8F 7.7%; P < 0.02) but
not by L-proline.
The kinetic parameters (i.e. Km and Vmax) of L-leucine
influx into MDA-MB-231 and MCF-7 cells were deter-
mined by incubating cells in media containing L-leucine
concentrations ranging from 10 AM to 2 mM. L-Leucine
uptake by MDA-MB-231 cells could be described by a
single-saturable curve (Fig. 2). The Km and Vmax were,respectively, 46F 14 AM and 6.66F 0.25 nmol/mg pro-
tein/30 s. Similarly, L-leucine uptake by MCF-7 cells could
also be described by a single-saturable curve despite the fact
that these cells express both LAT1 and LAT2 mRNA [21].
Thus, the Km and Vmax were, respectively, 179F 41 AM and
20.78F 0.52 nmol/mg protein/30 s. Both the Km (P < 0.05)
and Vmax (P < 0.001) of L-leucine uptake were lower in
MDA-MB-231 cells compared to the corresponding values
Table 1
The effect of 17h-estradiol on L-leucine uptake by MCF-7 and MDA-MB-
231 cells
Cell line 17h-Estradiol Vmax (nmol/mg/30 s) Km (AM)
MCF-7 + 13.38F 0.99* 233.5F 37.2
 8.86F 0.47 187.1F15.9
MDA-MB-231 + 9.72F 0.98 71.7F 8.7
 9.00F 1.02 60.5F 8.5
L-Leucine uptake was measured by MCF-7 and MDA-MB-231 cells which
had been incubated for 48 h in the absence and presence of 17h-estradiol
(10 nM). The incubation medium contained (mM) 0.01–2 L-leucine, 135
choline-Cl, 5 KCl, 2 CaCl2, 1 MgSO4, 10 glucose, 10 Tris–MOPS, pH 7.4
plus 1.0 ACi/ml [3H]L-leucine and 0.4 ACi/ml [14C]sucrose. Uptake was
measured at 37 jC over 30 s. Values shown are the meansF S.E. of five
and four experiments, respectively, when MCF-7 and MDA-MB-231 cells
were used.
*P < 0.001.
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uptake by MCF-7 cells as a function of the extracellular L-
alanine concentration. L-Alanine uptake was relatively low
under Na+-free conditions and operates with a Km>2 mM.
Fig. 3 shows that L-leucine uptake by MDA-MB-231 and
MCF-7 cells was inhibited by BCH in a dose-dependent
manner. The IC50 value for BCH inhibition of L-leucine
uptake into MDA-MB-231 and MCF-7 cells was, respec-
tively, 88.9F 7.6 and 175.9F 28.3 AM. Fig. 3 also illus-
trates the effect of the amino acid-related compound
melphalan on L-leucine uptake by MDA-MB-231 cells.
Melphalan inhibited L-leucine influx in a dose-dependent
manner: the IC50 was 82.5F 10.2 AM (F S.E., n = 3).
The effect of 17h-estradiol (10 nM) on the kinetics of
L-leucine uptake via system L in MCF-7 cells was exam-
ined. In this set of experiments, cells were cultured in
phenol red-free medium supplemented with charcoal-
stripped fetal bovine serum. Culturing MCF-7 cells with
17h-estradiol increased the Vmax of L-leucine uptake via
system L without affecting the Km (Table 1). Increasing the
concentration of 17h-estradiol to 100 nM had no further
effect on the Vmax (results not shown). Furthermore, 17h-
estradiol did not affect L-leucine uptake by MDA-MB-231
cells (Table 1).
5.2. L-Leucine efflux from MDA-MB-231 and MCF-7 cells
Preliminary experiments (Fig. 4, insets) established that
the efflux of L-leucine from MDA-MB-231 and MCF-7
cells measured under Na+-free conditions could be de-
scribed by a monoexponential equation. The efflux rate
constant and T1/2 (calculated from ln 2/k) for [
3H]L-leucine
efflux from MDA-MB-231 cells were, respectively,
0.100F 0.005 min 1 and 6.9F 0.4 min (F S.E., n = 3).Fig. 3. Dose-response of BCH-inhibition of L-leucine uptake by MDA-MB-
231 (n) and MCF-7 cells (.) and dose-response of melphalan inhibition of
L-leucine uptake by MDA-MB-231 cells (E). The incubation medium
contained (mM) 0–2 BCH or 0–2 melphalan, 135 choline-Cl, 5 KCl, 2
CaCl2, 1 MgSO4, 10 glucose and 10 Tris–MOPS, pH 7.4. Uptake was
assayed at 37 jC after 30 s of incubation. Each point is the meanF S.E. of
three to four experiments.The efflux rate constant and T1/2 for [
3H]L-leucine efflux
from MCF-7 cells were, respectively, 0.086F 0.001 min 1
and 8.1F 0.1 min (F S.E., n= 3). Importantly, [3H]L-leu-
cine and [14C]L-leucine effluxes were almost identical (Fig.
4, insets). On the basis of cost, it was decided to routinely
use [3H]L-leucine as tracer in subsequent experiments. The
effect of extracellular BCH, a paradigm substrate of system
L, on L-leucine efflux from MDA-MB-231 and MCF-7 cells
under Na+-free conditions was examined. Fig. 4a shows the
effect of BCH on L-leucine release from MDA-MB-231
cells. BCH trans-stimulated L-leucine efflux in a dose-
dependent fashion. Thus, BCH at a concentration of 10,
50, 100, 200 and 2000 AM stimulated L-leucine efflux
(basal-to-peak) by 130.0 F 5.2%, 313.2 F 16.8%,
492.6F 24.2%, 564.7F 11.9% and 664.3F 36.6%, respec-
tively. To determine the apparent affinity constant for BCH
at the external face of the carrier, we plotted V/Vo as a
function of ((V/Vo) 1)/[S] where Vo is L-leucine efflux in
the absence of external BCH, V is L-leucine efflux in the
presence of external BCH and [S] is the BCH concentration
in the medium. The apparent affinity constant was calculat-
ed from the slope of the plot. In applying this analysis we
have made the following two assumptions: (1) the concen-
trations of BCH in the cytosol and that of L-leucine in the
medium are zero at the start of the experiment; (2) the
concentration of L-leucine in the cell is markedly less than
its affinity for the internal face of the carrier [25]. The
affinity constant for BCH, calculated in this manner, was
44.5F 3.6 AM (F S.E.; n = 3). Extracellular BCH also
stimulated L-leucine efflux from MCF-7 cells in a dose-
dependent fashion (Fig. 4b). Thus, external BCH at a
concentration of 10, 50, 100 and 2000 AM increased L-
leucine efflux (basal-to-peak) by 73.8F 11.9%, 258.9F
10.3%, 410.4F 13.4%, 505.2F 19.2% and 740.9F69.1%,
respectively. The affinity constant for external BCH, calcu-
lated in a similar fashion to that described above, was
100.5F 20.5 AM(F S.E.; n = 4). Therefore, BCH stimulated
L-leucine efflux from MCF-7 cells with lower affinity
compared to MDA-MB-231 cells (P < 0.05).
Fig. 4. The effect of extracellular BCH on L-leucine efflux from (a) MDA-MB-231 and (b) MCF-7 cells. The incubation medium contained (mM) 135 choline-
Cl, 5 KCl, 2 CaCl2, 1 MgSO4, 10 glucose and 10 Tris–MOPS, pH 7.4. BCH was added to the incubation medium at a concentration of 1 AM (n), 10 AM (.),
50 AM (E), 100 AM (5) 200 AM (o) and 2000 AM (D). Efflux was assayed at 37 jC. Each point is the meanF S.E. of three and four experiments, respectively,
when MDA-MB-231 and MCF-7 cells were used. Insets show the time course of [3H]L-leucine (o) and [14C]L-leucine (.) efflux from MDA-MB-231 and
MCF-7 cells incubated in a medium containing (mM) 135 choline-Cl, 5 KCl, 2 CaCl2, 1 MgSO4, 10 glucose and 10 Tris–MOPS, pH 7.4. The plots are of ln
(Nt/No) as a function of time where Nt represents the amount of radioactivity in the cells at time t and No represents the amount of radioactivity in the cells at the
start of the incubation period.
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MDA-MB-231 and MCF-7 cells can operate as an amino
acid exchanger, it is apparent that L-leucine efflux per-
sisted in the absence of external substrate. There is the
possibility that amino acids released from the cells viaalternative pathways could have acted to trans-stimulate
L-leucine release. However, pre-incubating MDA-MB-231
cells for 1 h in an amino acid-free medium (with frequent
change of the medium), to reduce the intracellular amino
acid pool, did not diminish the fractional efflux of L-
Table 2
The effect of external amino acids on L-leucine efflux from MDA-MB-231
cells
Fractional efflux (min 1) 10 2
Amino acid n Amino
acid
+Amino
acid
Difference t P
L-Leucine 3 7.37F 0.59 63.38F 4.49 56.01F 4.87 1 < 0.01
D-Leucine 3 8.04F 0.79 69.90F 4.39 61.86F 3.79 1 < 0.01
L-Alanine 4 8.98F 0.81 42.48F 3.21 33.50F 3.66 2 < 0.01
D-Alanine 4 8.02F 0.61 12.77F 0.98 4.75F 0.46 5 < 0.01
L-Glutamine 3 8.57F 0.65 50.00F 1.85 41.43F 2.17 1 < 0.01
L-Lysine 5 10.28F 0.66 22.88F 3.26 12.60F 3.04 2 < 0.02
L-Lysine
(6 mM)
3 9.26F 0.64 31.69F 3.06 22.43F 2.67 2 < 0.02
L-Arginine 3 11.69F 1.26 12.76F 1.61 – – NS
AIB 3 11.76F 1.71 34.91F1.12 23.15F 2.53 3 < 0.02
L-Proline 3 9.29F 1.04 10.64F 1.60 – – NS
L-Glutamate 4 13.32F 1.10 16.32F 1.19 – – NS
Melphalan 3 13.26F 1.51 11.84F 0.58 – – NS
Cells were incubated in a medium containing (mM) 135 choline-Cl, 5 KCl,
2 CaCl2, 1 MgSO4, 10 glucose and 10 Tris–MOPS, pH 7.4. Amino acids
were used at a final concentration of 2 mM unless otherwise indicated. t
represents the time taken for the fractional efflux to reach the peak value.
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apparent zero-trans conditions. Therefore, the efflux of L-
leucine measured from cells incubated in an amino acid-
free buffer could possibly represent uncoupled transport
via system L. To investigate this further, we examined the
effect of temperature on L-leucine release from the two
human breast cancer cell lines. Fig. 5 shows the effect of
external BCH (2 mM) on leucine efflux from MDA-MB-
231 cells measured at 37 and 4 jC. Reducing the
temperature almost abolished the effect of extracellular
BCH on L-leucine efflux. It is notable, however, that L-
leucine efflux in the absence of BCH was also temper-
ature-sensitive, suggesting that this moiety of efflux is
carrier-mediated. Thus, L-leucine efflux from MDA-MB-
231 cells was reduced from 0.0831F 0.0042 to
0.0236F 0.0027 min 1 (F S.E.; n = 3; P < 0.001). Simi-
larly, reducing the temperature of the incubation medium
reduced L-leucine efflux from MCF-7 cells under zero-
trans conditions from 0.0808F 0.0118 to 0.0303F 0.0046
min 1 (F S.E.; n = 3; P < 0.02).
We examined the effect of a wide range of external
amino acids (all tested at 2 mM) on L-leucine efflux from
MDA-MB-231 cells in order to establish which amino acids
are transported substrates. In this set of experiments, the
efflux of L-leucine was initially measured from cells incu-
bated in an amino-acid-free medium followed by a buffer
containing a ‘test’ amino acid. The amino acids examined
were L-leucine, D-leucine, L-glutamine, L-alanine, D-alanine,Fig. 5. L-Leucine efflux from MDA-MB-231 cells in the absence and MCF-7
cells in the absence and presence of external BCH measured at 37 jC (n)
and 4 jC (.). The incubation medium contained (mM) 135 choline-Cl, 5
KCl, 2 CaCl2, 1 MgSO4, 10 glucose and 10 Tris–MOPS, pH 7.4. BCH,
when required, was used at a concentration of 2 mM. Each point is the
meanF S.E. of three observations.L-proline, L-lysine, L-arginine, L-glutamate and AIB. Table 2
shows that L-leucine, D-leucine, L-alanine and L-glutamine
stimulated L-leucine release from MDA-MB-231 cells. AIB,
L-lysine and D-alanine also trans-accelerated L-leucine ef-
flux though less effectively than those just mentioned. In
contrast, L-proline, L-arginine and L-glutamate had no sig-
nificant effect on L-leucine efflux from MDA-MB-231 cells.
The effect of amino acids on L-leucine efflux from MCF-7
cells showed a similar pattern (Table 3). Thus, L-glutamine,
L-alanine and L-leucine and, to a lesser extent, AIB and L-
lysine all trans-stimulated L-leucine efflux whereas L-pro-
line and D-alanine were without effect.
The effect of external melphalan (2 mM) on L-leucine
efflux from MDA-MB-231 cells was examined. Melphalan
failed to trans-stimulate L-leucine release (Table 2). How-
ever, the effect of external BCH (0.5 mM) on L-leucine
efflux from MDA-MB-231 cells was markedly reduced in
the presence of external melphalan (2 mM) (results not
shown).Table 3
The effect of external amino acids on L-leucine efflux from MCF-7 cells
Fractional efflux (min 1) 10 2
Amino acid n Amino acid +Amino acid Difference t P
L-Leucine 4 7.81F 0.53 66.62F 0.64 58.81F 0.98 1 < 0.001
D-Leucine 3 7.91F 0.32 72.25F 0.16 64.34F 0.19 1 < 0.001
L-Alanine 4 8.52F 0.95 27.44F 0.77 18.92F 0.25 3 < 0.001
D-Alanine 3 7.97F 0.47 11.02F 0.11 – – NS
L-Glutamine 5 8.55F 0.49 44.80F 0.31 36.25F 0.71 2 < 0.001
L-Lysine 4 8.24F 0.51 16.11F 0.26 7.87F 2.36 3 < 0.05
AIB 3 8.77F 0.63 26.09F 0.19 17.32F 1.38 3 < 0.01
L-Proline 3 7.64F 0.21 7.29F 0.61 – – NS
Cells were incubated in a buffer containing (mM) 135 choline-Cl, 5 KCl, 2
CaCl2, 1 MgSO4, 10 glucose and 10 Tris–MOPS, pH 7.4. Amino acids
were used at a final concentration of 2 mM. t represents the time taken for
the fractional efflux to reach a peak value.
Table 4
Quantitative expression of LAT1, LAT2 and CD98 mRNA in MDA-MB-
231 and MCF-7 cells
Transcripts per 40 ng of total RNA ( 103)
LAT1 LAT2 CD98hc
MDA-MB-231 116.0F 7.2 ND 27.1F1.9*
MCF-7 197.5F 20.8a 0.91F 0.10y 39.8F 7.3**
Values are meansF S.E. of three experiments. ND—not detected. CD98hc
vs. LAT1 in both MCF-7 and MDA-MB-231 cells, *P< 0.02, **P< 0.01;
LAT1 vs. LAT2 in MCF-7 cells, y P < 0.02; MCF-7 vs. MDA-MB-231
LAT1 levels a P < 0.05.
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We examined the quantitative expression of LAT1, LAT2
and CD98hc in MDA-MB-231 and MCF-7 cells using real-
time quantitative PCR (Table 4). The results confirm recent
findings that MCF-7 cells express LAT1, LAT2 and CD98hc
mRNA whereas MDA-MB-231 cells express LAT1 and
CD98hc mRNA [21]. We now show that: (1) LAT1 mRNA
is approximately 200 times more abundant than LAT2
mRNA in MCF-7 cells; (2) LAT1 mRNA is more abundant
than CD98hc mRNA in both MCF-7 and MDA-MB-231
cells; (3) LAT1 mRNA is more abundant in MCF-7 cells
than in MDA-MB-231 cells; and (4) CD98hc mRNA is
more abundant than LAT2 mRNA in MCF-7 cells.6. Discussion
6.1. L-Leucine is mediated by system L in human breast
cancer cells
The results show that L-leucine uptake by MDA-MB-231
and MCF-7 cells is via a Na+-independent, BCH-sensitive
pathway, which is consistent with L-leucine uptake via
system L. Indeed, it appears that system L may be the
major, if not the sole, pathway for L-leucine uptake. This
suggests that system L may play a crucial role in breast
cancer cell growth by providing both cell types with
essential neutral amino acids such as L-leucine. In this
connection, a recent report from our laboratory also suggests
that system L may be the major pathway for L-tryptophan
uptake by MBA-MB-231 cells [26].
The present results are in accordance with our recent
finding that AIB is transported via system L in both MDA-
MB-231 andMCF-7 cells [21]. AIBwas used to study system
L in the two cell lines because we wanted to avoid the
confounding issue of amino acid metabolism. Although
AIB proved to be a useful tool for the initial characterization
of system L [21], it has to be borne in mind that non-
metabolizable amino acid analogues do have some limita-
tions. In particular, the rate of AIB transport does not always
approximate with that of naturally occurring amino acids. In
this connection, the kinetic parameters of L-leucine and AIB
uptake via system L aremarkedly different. Thus, theKm of L-leucine uptake in MDA-MB-231 and MCF-7 cells is more
than an order of magnitude smaller than that of AIB uptake.
On the other hand, the Vmax of L-leucine uptake by both cell
lines is more than an order of magnitude greater than that of
AIB uptake. Even though there was the possibility that L-
leucine could have been subjected to metabolism, especially
during the efflux experiments, there is evidence to suggest
that L-leucine was a suitable substrate to use. First, the
characteristics of Na+-independent, BCH-sensitive L-leucine
and AIB transport were similar. For example, those amino
acids which were found to trans-accelerate AIB efflux also
stimulated L-leucine efflux from both cell lines. Second, the
effluxes of [14C]L-leucine and [3H]L-leucine were almost
indistinguishable suggesting that metabolism may have been
minimal.
6.2. Regulation of system L by estrogen
The results suggest that estrogen (17h-estradiol) regu-
lates L-leucine uptake via system L in MCF-7 cells: the
Vmax of L-leucine uptake was increased whereas the Km
was unchanged. The effect appears to be specific given
that 17h-estradiol had no effect on L-leucine uptake by
estrogen receptor-negative MDA-MB-231 cells. In this
connection, it has been reported that estrogen increases
the expression of E16 (LAT1) in ZR75-1 cells (an estrogen
receptor-positive human breast cancer cell line) [27]. It is
tempting to suggest that estrogen may be a general
regulator of amino acid transport in estrogen receptor-
positive cells given that system A expression and activity
in MCF-7 cells is also up-regulated by 17h-estradiol [28].
It is envisaged that estrogen could contribute to the
proliferative capacity of estrogen receptor-positive breast
cancer cells by increasing amino acid uptake via systems
A and L.
The Vmax of L-leucine uptake via system L was higher in
MCF-7 cells than MDA-MB-231 cells when the cells are
cultured in DMEM containing phenol red (see Fig. 2).
However, this difference was abolished by culturing MCF-
7 and MDA-MB-231 cells in phenol red-free DMEM
supplemented with charcoal-stripped fetal bovine serum.
This is consistent with the finding that estrogen regulates
L-leucine transport via system L in MCF-7 cells.
6.3. Can system L activity in MDA-MB-231 and MCF-7
cells be ascribed to LAT1 and/or LAT2?
The data suggest that MDA-MB-231 cells express sys-
tem L at the functional and molecular level. One important
question that arises is: can the properties of system L in
MDA-MB-231 cells be attributed to LAT1? L-Leucine
transport in MDA-MB-231 cells shares many characteristics
with amino acid transport via LAT1. For example, the Km of
L-leucine uptake is similar to that of L-leucine transport via
LAT1 in T24 bladder cells [5]. The interaction of D-leucine
with L-leucine transport is also reminiscent of LAT1. In
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231 cells can be trans-accelerated is characteristic of LAT1.
However, some of the properties of L-leucine transport in
MDA-MB-231 cells are different from that of LAT1. In
particular, we have confirmed the rather curious finding that
L-lysine interacts with system L in MDA-MB-231 cells. The
present results imply that L-lysine is actually a transported
substrate. In contrast, LAT1 does not appear to accept L-
lysine as substrate (e.g. see Ref. [9]). We must stress that the
interaction between L-lysine and system L is one of low
affinity. We also found that external L-alanine, which is
considered not to be a substrate of LAT1, stimulated L-
leucine efflux from MDA-MB-231 cells. However, L-ala-
nine uptake (10 AM) by MDA-MB-231 cells under Na+-free
conditions was extremely low in comparison to L-leucine
influx, suggesting that the former is a relatively poor (low
affinity) substrate. Nevertheless, the results of the present
study suggest that LAT1 in MDA-MB-231 human breast
cancer cells can operate with a relatively wide substrate
specificity. Alternatively, other molecular forms may con-
tribute to system L activity in MDA-MB-231 cells. On the
basis of kinetics and substrate specificity, we can rule out
the recently discovered LAT3 molecular form of system L
as being a major contributor to L-leucine uptake in MDA-
MB-231 cells [16].
Attributing the characteristics of system L activity in
MCF-7 cells to a particular molecular form is more difficult
given that LAT1 and LAT2 are both expressed. However,
the finding that LAT1 mRNA is approximately 200 times
more abundant than LAT2 mRNA suggests that LAT1 may
make a larger contribution to system L activity. The kinetics
of L-alanine uptake by MCF-7 cells also suggests that the
contribution of LAT2 to system L activity is relatively small.
The ratio of L-leucine to L-alanine uptake (at a concentration
of 0.1 mM) by MCF-7 cells is 51:1 whereas the ratio of L-
leucine to L-alanine uptake by LAT2 expressed in Xenopus
oocytes is approximately 2:1 [15].
6.4. Transport of melphalan by MDA-MB-231 cells
System L in MDA-MB-231 cells was inhibited by the
anti-cancer agent melphalan. This is consistent with the
notion that melphalan can gain entry into cells via system
L [5,22]. However, we found that melphalan did not trans-
stimulate L-leucine efflux from MDA-MB-231 cells, sug-
gesting that it is transported slowly. Indeed, the rate of
melphalan transport may be so low in comparison to
amino acids that it acts more like a blocker than a
transported substrate. It is predicted that melphalan at
suitably high concentrations could inhibit the uptake of
certain essential amino acids (e.g. L-leucine and L-trypto-
phan) into breast cancer cells. However, it must be borne
in mind that firm conclusions regarding the effect of
melphalan (and indeed BCH) on system L rely on the
assumption that the effects of the compounds are relatively
specific.6.5. Can system L act as both an exchanger and a
uniporter?
LAT1 operates as an amino acid exchange mechanism
[9,29]. However, the mode of operation of LAT2 is a matter
of controversy. On the one hand, it has been reported that
LAT2 operates as an amino acid exchanger [12,15,29]. On
the other hand, there is evidence to suggest that amino acid
efflux via LAT2 is not dependent upon extracellular amino
acids [13,30]. The operating mode of system L is important
regarding its relationship with other amino acid transport
mechanisms [23,29]. If, for instance, system L acts as a
tightly coupled amino acid exchanger, it could not by itself
accomplish net transport. Rather, it must function in parallel
with other transport systems which have overlapping sub-
strate specificity [23]. However, this need not be the case if
system L allows some slippage. In this connection, we have
confirmed that system L in MDA-MB-231 and MCF-7 cells
is able to operate as an amino acid exchange mechanism.
Thus, BCH stimulated L-leucine efflux from both human
breast cancer cell lines with relatively high affinity. Other
amino acids which trans-stimulated L-leucine efflux and
which must be regarded as transported substrates include L-
alanine, L-glutamine, AIB and D-leucine. However, system
L in human breast cancer cells may also act as a uniporter.
This notion is based on the finding that there is a significant
amount of L-leucine efflux from MDA-MB-231 and MCF-7
cells under zero-trans conditions. This portion of L-leucine
efflux can be reduced by lowering the temperature of the
incubation medium, suggesting that it is carrier-mediated. In
addition, it has recently been shown that there is a signif-
icant efflux of AIB from human breast cancer cell lines
incubated in an amino acid-free buffer [21]. We feel that it is
reasonable to suggest that this moiety of efflux may be
uncoupled amino acid transport via system L. There are
several lines of evidence that system L in other cell types is
able to mediate net transport of amino acids. First, net (i.e.
uncoupled) BCH transport occurs in human T-lymphocytes
[31]. Second, despite the finding that lactating rat mammary
tissue expresses system L at the molecular (LAT1 and
LAT2) and functional level [32], amino acid efflux from
mammary tissue explants was not trans-stimulated by sys-
tem L substrates [33,34]. Third, Segawa et al. [13] and Liu
et al. [30] have shown that LAT2 is capable of acting as a
uniporter. Therefore, it appears that system L in some cells
may not have to rely on other transporters to accomplish net
transport.
6.6. Relative expression of LAT1, LAT2 and CD98 mRNA
The present study confirms that MCF-7 cells express
LAT1, LAT2 and CD98hc mRNA but that MDA-MB-231
cells express only LAT1 and CD98hc mRNA. A new
finding is that the abundance of LAT1 mRNA is markedly
greater than that of CD98hc mRNA in both cell lines. The
ratio of LAT1/CD98hc mRNA in MDA-MB-231 and MCF-
hysica Acta 1664 (2004) 206–216
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Kim et al. [5] have reported that LAT1 mRNA is approx-
imately 1.5 times higher than CD98hc mRNA in T24
human bladder carcinoma cells. It is interesting to note that
the concentration of LAT1 mRNA found in T24 cells
by Kim et al. [5] is comparable to that found by us in
MDA-MB-231 and MCF-7 cells (10.44F 0.97 10 18,
8.20F 0.86 10 18 and 4.82F 0.29 10 18 mol/Ag of
total RNA for T24, MCF-7 and MDA-MB-231 cells,
respectively). The high ratio of LAT1/CD98 in the two
mammary cancer cell lines appears to be unusual given that
the expression of the heavy chain, but not the light chain,
correlates with the induction of system L activity in human
placental villous explants [35]. The significance of the
LAT1/CD98hc mRNA ratio awaits the determination of
relevant LAT1 and CD98 protein abundances and cellular
location.Acknowledgements
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